
Sarepta Therapeutics (SRPT) Stock Forecast & Price Target
Sarepta Therapeutics (SRPT) Analyst Ratings
Bulls say
Sarepta Therapeutics Inc. is positioned for significant financial improvement, with the transition to a new manufacturing process set to enhance margins to approximately 90% for its gene therapy programs by 2027. The company's robust commercial execution is anticipated to propel sales, with projections estimating FY 2025 Elevidys sales at around $2.2 billion, reflecting a strong growth trajectory. Furthermore, the successful growth of the Vyondys product in Q4 2024 and the overall revenue expectations paint a positive outlook for the company's financial performance in the coming years.
Bears say
Sarepta Therapeutics faces significant risks that negatively impact its outlook, including the potential for lower-than-expected sales from its commercial products and concerns related to gene therapy safety signals from ongoing trials. The company's focus on rare diseases may lead to delays in patient recruitment, which would adversely affect sales estimates, compounded by flat sales for its Amondys product and a slight decline for Exondys, alongside increasing competition from alternative therapies. Furthermore, the early-stage nature of many of its product candidates, combined with potential regulatory hurdles, casts uncertainty over the company's ability to achieve its projected market potential.
This aggregate rating is based on analysts' research of Sarepta Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Sarepta Therapeutics (SRPT) Analyst Forecast & Price Prediction
Start investing in Sarepta Therapeutics (SRPT)
Order type
Buy in
Order amount
Est. shares
0 shares